QuidelOrtho Corp is a prominent player in the field of medical diagnostics, specializing in the development and manufacture of diagnostic testing solutions. The company focuses on producing innovative products that aid in the rapid detection of infectious diseases and other critical health conditions, utilizing advanced technologies such as molecular diagnostics and immunoassay platforms. QuidelOrtho's portfolio includes a range of tests designed for use in various healthcare settings, including hospitals, laboratories, and physician offices, facilitating timely and accurate diagnoses that enhance patient care. Through its commitment to innovation and quality, the company strives to improve the health outcomes of individuals around the globe.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the “Board”), effective December 6, 2024.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company’s common stock (“Common Stock”).
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company’s common stock (“Common Stock”).
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the third quarter ended September 29, 2024.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its third quarter 2024 ended September 29, 2024, after the market close on Thursday, November 7, 2024.
QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024.
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.
QuidelOrtho Corporation (Nasdaq: QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho’s human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer.
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its VITROS syphilis assay as part of its menu, strengthening QuidelOrtho’s position as a leader in infectious disease testing. Using the automated VITROS systems, this assay is intended for the qualitative determination of total (IgG and IgM) antibodies to Treponema pallidum (TP)-specific antigens in human serum and plasma using the automated VITROS 3600, 5600 and XT 7600 systems. The presence of antibodies to TP-specific antigens, in conjunction with non-treponemal laboratory tests and clinical findings may aid in the diagnosis of syphilis infection. The VITROS syphilis assay is not intended for blood and tissue donor screening. With the addition of the U.S., the VITROS syphilis assay is now available globally where QuidelOrtho products are available.
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend two upcoming investor conferences.
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against QuidelOrtho Corporation (NASDAQ: QDEL) on behalf of long-term stockholders following a class action complaint that was filed against QuidelOrtho on April 12, 2024 with a Class Period from February 18, 2022 to April 1, 2024. Our investigation concerns whether the board of directors of QuidelOrtho have breached their fiduciary duties to the company.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the second quarter ended June 30, 2024.
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2024 ended June 30, 2024, after the market close on Wednesday, July 31, 2024.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against QuidelOrtho Corporation (NASDAQ: QDEL) on behalf of long-term stockholders following a class action complaint that was filed against QuidelOrtho on April 12, 2024 with a Class Period from February 18, 2022 to April 1, 2024. Our investigation concerns whether the board of directors of QuidelOrtho have breached their fiduciary duties to the company.
